Clinical Trials
ISSUE NO. 7 — Understanding the Intrinsic and Extrinsic Factors that Alter Drug Exposure and Toxicity
Up Close and Personal with Ingrid Holmes
Ingrid joined Altasciences in 2011, as Vice President of Clinical Operations at the Montreal site, a facility currently housing seven clinical units with 265 beds, and dedicated
ISSUE NO. 5 — Metabolic Disorders (Obesity, Diabetes, NAFLD/NASH) — Updated 2021
Metabolic disorders are conditions that disrupt normal metabolism and the process of converting food to energy at the cellular level.
Pain – is it all in your head?
Pain is a fascinating phenomenon, acting as a physiological warning system that alerts us of potential dangers in our environment.
ISSUE NO. 4 — Key Considerations for Biosimilar Clinical Pharmacology Studies
Topical and Transdermal – Getting Under Your Skin
The skin is the largest organ of the human body, measuring 22 square feet, on average.
WHAT IT TAKES — Central Nervous System (CNS) Clinical Trials
Biopharmaceutical companies developing new CNS products can face special obstacles.
ISSUE NO. 3 — Assessing Human Abuse Potential to Limit the Misuse and Abuse of Prescription Drugs
Patient Centricity — taking care of our most valuable asset!
“Patient centricity” is the process of designing a service or solution around the patient; more specifically, it is collectively defined as “Putting the patient fi
Because who Doesn’t Love a Quiz!